Better treatment for breast cancer in older patients

References

• Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide. In: IARC CancerBase (5 Version 2.0). Lyon: IARCPress GLOBOCAN (Eds). (2004).
   Google Scholar
• Ballard-Barbash R, Potosky AL, Harlan LC et al. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J. Natl Cancer Inst.88, 716–726 (1996).
   PubMed Web of Science ®Google Scholar
• Freyer G, Braud AC, Chaibi P et al. Dealing with metastatic breast cancer in elderly women: results from a french study on a large cohort carried out by the “observatory on elderly patients”. Ann. Oncol.17, 211–216 (2006).
   PubMed Web of Science ®Google Scholar
• Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl Cancer Inst.92, 550–556 (2000).
   PubMed Web of Science ®Google Scholar
• Grann VR, Troxel AB, Zojwalla NJ et al. Hormone receptor status and survival in a population based cohort of patients with breast carcinoma. Cancer103, 2241–2251 (2005).
   PubMed Web of Science ®Google Scholar
• Pierga JY, Girre V, Laurence V et al. Characteristic and outcome of 1755 operable breast cancers in women over 70 years of age. Breast13, 369–375 (2004).
   PubMed Web of Science ®Google Scholar
• Daidone MG, Coradini D, Martelli G et al. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit. Rev. Oncol. Hematol.45, 313–325 (2003).
   PubMed Web of Science ®Google Scholar
• Molino A, Giovannini M, Auriemma A et al. Pathological, biological and clinical characteristics, and surgical management of elderly women with breast cancer. Crit. Rev. Oncol. Hematol.59, 226–233 (2006).
   PubMed Web of Science ®Google Scholar
• Gennari R, Curigliano G, Rotmensz N et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. Cancer101, 1302–1310 (2004).
   PubMed Web of Science ®Google Scholar
• Singh R, Hellman S, Heimann R. The natural history of breast carcinoma in the elderly: implications for screening and treatment. Cancer100, 1807–1813 (2004).
   PubMed Web of Science ®Google Scholar
• Humphrey LL, Helfand M, Chan BK et al. Breast cancer screening: a summary of the evidence for the USA preventive services task force. Ann. Intern. Med.137, 347–360 (2002).
   PubMed Web of Science ®Google Scholar
• Vainio H, Bianchini F. Breast cancer screening. In: IARC Handbooks of Cancer Prevention (Volume 7). Lyon IARC Press, France (2002).
   Google Scholar
• Nystrom L, Andersson I, Bjurstam N et al. Long-term effects of mammography screening: updated overview of the Swedish randomized trials. Lancet359, 909–919 (2002).
   PubMed Web of Science ®Google Scholar
• Galit W, Green MS, Lital KB. Routine screening mammography in women older than 74 years: a review of the available data. Maturitas57, 109–119 (2007).
   PubMed Web of Science ®Google Scholar
• Fracheboud J, Groenewoud JH, Boer R et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening. Int. J. Cancer118, 2020–2025 (2006).
   PubMed Web of Science ®Google Scholar
• Walter LC, Lewis CL, Barton MB. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am. J. Med.118, 1078–1086 (2005).
   PubMed Web of Science ®Google Scholar
• Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer. CA Cancer J. Clin.54, 41–52 (2004).
   PubMed Web of Science ®Google Scholar
• Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J. Clin. Oncol.18, 1709–1717 (2000).
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Siminoff L, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol.19, 980–991 (2001).
   PubMed Web of Science ®Google Scholar
• Yancik R, Wesley MN, Ries LAG et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA285, 885–892 (2001).
   PubMed Web of Science ®Google Scholar
• Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian group for geriatric oncology study. J. Clin. Oncol.20, 494–502 (2002).
   PubMed Web of Science ®Google Scholar
• Extermann M, Aapro M, Bernabei R et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the international society of geriatric oncology (SIOG). Crit. Rev. Oncol. Hematol.55, 241–252 (2005).
   PubMed Web of Science ®Google Scholar
• Mandelblatt JS, Bierman AS, Gold K, Zhang Y, Ng JH, Maserejan N. Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv. Res.36(6), 1085–1107 (2001).
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet366, 2087–3106 (2005)
   PubMed Web of Science ®Google Scholar
• Kiebert GM, de Haes JCJM, van de Velde CJH. Quality of life after mastectomy and breast conserving surgery: a review. J. Clin. Oncol.9, 1059–1070 (1991).
   PubMed Web of Science ®Google Scholar
• Poulsen B, Graversen HP, Beckmann J, Blichert-Toft M. A comparative study of postoperative psychosocial function in omen with primary operable breast cancer randomized to breast conservation therapy or mastectomy. Eur. J. Surg. Oncol.23, 327–334 (1997).
   PubMed Web of Science ®Google Scholar
• Curran D, Van Dongen JP, Aaronson NK et al. On behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group (BCCG). Quality of life of early breast cancer patients treated with radical mastectomy or breast conserving procedures: results of EORTC Trials 10801. Eur. J. Cancer34, 307–314 (1998).
   PubMed Web of Science ®Google Scholar
• McKenna RJ. Clinical aspects of cancer in the elderly. Treatment decisions, treatment choices and follow up. Cancer74(Suppl.), 2107–2117 (1994).
   PubMed Web of Science ®Google Scholar
• Merchant TE, McCormick B, Yahalom J, Borgen P. The influence of older age on breast cancer treatment decisions and outcome. Int. J. Radiat. Oncol. Biol. Phys.34, 565–570 (1996).
   PubMed Web of Science ®Google Scholar
• Morrow M, Bucci C, Rademaker A. Medical contraindications are not a major factor in the underutilization of breast conserving therapy. J. Am. Coll. Surg.186, 269–274 (1998).
   PubMed Web of Science ®Google Scholar
• Repetto L, Costantini M, Campora E et al. A retrospective comparison of detection and treatment of breast cancer in young and elderly patients. Breast Cancer Res. Treat.43, 27–31 (1997).
   PubMed Web of Science ®Google Scholar
• Wanebo HJ, Cole B, Chung M et al. Is surgical management compromised in elderly patients with breast cancer? Ann. Surg.225, 579–586 (1997).
   PubMed Web of Science ®Google Scholar
• Guadagnoli E, Weeks JC, Shapiro CL et al. Use of breast conserving surgery for treatment of stage I and stage II breast cancer. J. Clin. Oncol.16, 101–106 (1998).
   PubMed Web of Science ®Google Scholar
• Jubelirer SJ, Larzo CR. The treatment of breast cancer in the elderly: a community hospital experience. W. V. Med. J.94, 329–331 (1998).
   PubMedGoogle Scholar
• Fentiman IS, Tirelli U, Monfardini S et al. Cancer in the elderly: why so badly treated? Lancet335, 1020–1022 (1990).
   PubMed Web of Science ®Google Scholar
• Robb C, Haley WE, Balducci L et al. Impact of breast cancer survivorship on quality of life in older women. Crit. Rev. Oncol. Hematol.62, 84–91 (2007).
   PubMed Web of Science ®Google Scholar
• Ganz PA, Guadagnoli E, Landrum MB, Lash TL, Rakowski W, Silliman RA. Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J. Clin. Oncol.21, 4027–4033 (2003).
   PubMed Web of Science ®Google Scholar
• Arndt V, Merx H, Stürmera T, Stegmaier C, Ziegler H, Brenner H. Age-specific detriments to quality of life among breast cancer patients one year after diagnosis. Eur. J. Cancer40, 673–680 (2004).
   PubMed Web of Science ®Google Scholar
• Ballard-Barbash R, Potosky AL, Harlan LC, Nayfield SG, Kessle LG. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J. Natl Cancer Inst.88, 716–726 (1996).
   PubMed Web of Science ®Google Scholar
• Enger SM, Thwin SS, Buist DM et al. Breast cancer treatment among older women in integrated health care settings. J. Clin. Oncol.24(27), 4377–4383 (2006).
   PubMed Web of Science ®Google Scholar
• Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL. The consequence of undertreating breast cancer in the elderly. J. Am. Coll. Surg.192, 698–707 (2001).
   PubMed Web of Science ®Google Scholar
• Hébert-Croteau N, Brisson J, Latreille J, Blanchette C, Deschênes L. Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women. Cancer85, 1104–1113 (1999).
   PubMed Web of Science ®Google Scholar
• Truong PT, Bernstein V, Wai E, Chua B, Speers C, Olivotto IA. Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1–ST2 breast cancer. Int. J. Radiat. Oncol. Biol. Phys.54(3), 794–803 (2002).
   PubMed Web of Science ®Google Scholar
• Yood MU, Owusu C, Buist DM, Geiger AM, Field TS, Thwin SS. Mortality impact of less-than-standard therapy in older breast cancer patients. J. Am. Coll. Surg.206, 66–75 (2008).
   PubMed Web of Science ®Google Scholar
• Fentiman IS, van Zyl J, Karydas I et al. Treatment of operable breast cancer in the elderly: a randomized clinical trial EORTC 10850 comparing modified radical mastectomy with tumorectomy plus tamoxifen. Eur. J. Cancer39, 300–308 (2003).
   PubMed Web of Science ®Google Scholar
• De Haes JCJ, Curran D, Aaronson NK, Fentiman IS; on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group (BCCG). Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomized clinical trial. Eur. J. Cancer39, 945–951 (2003).
   PubMed Web of Science ®Google Scholar
• Hughes KS, Schnaper LA, Berry D et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years or older with early breast cancer. N. Engl. J. Med.351, 971–977 (2004).
   PubMed Web of Science ®Google Scholar
• Litvak DA, Arora R. Treatment of elderly, breast cancer patients in a community hospital setting. Arch. Surg.141, 985–990 (2006).
   PubMedGoogle Scholar
• Hack TF, Cohen L, Katz J, Robson LS, Goss P. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J. Clin. Oncol.17, 143–149 (1999).
   PubMed Web of Science ®Google Scholar
• Mandelblatt JS, Edge SB, Meropol NJ et al. Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J. Clin. Oncol.21, 855–863 (2003).
   PubMed Web of Science ®Google Scholar
• Martelli G, Miceli R, De Palo G et al. Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla? Cancer97, 1156–1163 (2003).
   PubMed Web of Science ®Google Scholar
• Martelli G, Boracchi P, De Palo M et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer – results after 5 years of follow-up. Ann. Surg.242, 1–6 (2005).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med.349, 546–553 (2003).
   PubMed Web of Science ®Google Scholar
• Rudenstam CM, Zahrieh D, Forbes JF et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10–93. J. Clin. Oncol.24(3), 337–344 (2006).
   PubMed Web of Science ®Google Scholar
• Krag D, Weaver D, Ashikaga T et al. The sentinel node in breast cancer: a multicenter validation study. N. Engl. J. Med.339, 941–946 (1998).
   PubMed Web of Science ®Google Scholar
• McMahon LE, Gray RJ, Pockaj BA. Is breast cancer sentinel lymph node mapping valuable for patients in their seventies and beyond? Am. J. Surg.190, 366–370 (2005).
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol.17, 460–469 (1999).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Orecchia R, Zurrida S et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann. Oncol.16, 383–388 (2005).
   PubMed Web of Science ®Google Scholar
• Lyman GH, Giuliano AE, Somerfield MR et al. American Society of Clinical oOncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J. Clin. Oncol.23, 7703–7720 (2005).
   PubMed Web of Science ®Google Scholar
• Gennari R, Rotmensz N, Perego E, Santos GD, Veronesi U. Sentinel node biopsy in elderly breast cancer patients. Surg. Oncol.13, 193–196 (2004).
   PubMed Web of Science ®Google Scholar
• Rubens RD, Richards MA, Ramirez AJ et al. Large operable breast cancer: the applicability of primary chemotherapy. Breast6, 45–50 (1997).
   Web of Science ®Google Scholar
• Figueiredo MI, Cullen J, Hwang YT, Rowland JH, Mandelblatt JS. Breast cancer treatment in older women: does getting what you want improve your long-term body image and mental health. J. Clin. Oncol.22, 4002–4009 (2004).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol.16, 1569–1583 (2005).
   PubMed Web of Science ®Google Scholar
• Eifel P, Axelson JA, Costa J et al. National Institute of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J. Natl Cancer Inst.93, 979–989 (2001).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet365, 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Crivellari D, Price K, Gelber RD et al. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer. 21-year results of International Breast Cancer Study Group Trial IV. J. Clin. Oncol.21, 4517–4523 (2003).
   PubMed Web of Science ®Google Scholar
• ATAC Trialists Group: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol.9(1), 45–53 (2008).
   PubMed Web of Science ®Google Scholar
• The Breast International Group BIG 1–98. Randomized double-blind Phase III study to evaluate letrozole (L) versus tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. N. Engl. J. Med.353, 2747–2757 (2005).
   PubMed Web of Science ®Google Scholar
• Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor-positive breast cancer: Status Report 2004. J. Clin. Oncol.23, 619–629 (2005).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med.350, 1081–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole (ITA) trial. J. Clin. Oncol.23, 5138–5147 (2005).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet366, 455–462 (2005).
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl Cancer Inst.97, 1262–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Greil R, Gnant M et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J. Natl Cancer Inst.99, 1845–1853 (2007).
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, De Laet C et al. International variation in hip fracture probabilities: implications for risk assessment. J. Bone Miner. Res.17, 1237–1244 (2002).
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J. Am. Geriatr. Soc.51, 364–370 (2003).
   PubMed Web of Science ®Google Scholar
• Jones SE, Seynaeve C, Hasenburg A et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized Phase III trial in hormone sensitive postmenopausal breast cancer. SABCS (2008) (Abstract 15).
   Google Scholar
• Osborne CK, Schiff R. Aromatase inhibitors: future directions. J. Steroid Biochem. Mol. Biol.95, 183–187 (2005).
   PubMed Web of Science ®Google Scholar
• Smith BD, Gross CP, Smith GL, Galusha DH, Bekelman JE, Haffty BG. Effectiveness of radiation therapy for older women with early breast cancer. J. Natl Cancer Inst.98, 681–690 (2006).
   PubMedGoogle Scholar
• Herskind C, Steil V, Kraus-Tiefenbacher U, Wenz F. Radiobiological aspects of intraoperative radiotherapy (IORT) with Isotropic low-energy X rays for early-stage breast cancer. Radiat. Res.163, 208–215 (2005).
   PubMed Web of Science ®Google Scholar
• Gazet JC, Ford H, Coombes RC. Prospective randomized trial of tamoxifen versus surgery in elderly patients with breast cancer. Eur. J. Surg. Oncol.20, 207–214 (1994).
   PubMedGoogle Scholar
• Kenny FS, Robertson JFR, Ellis IO, Elston CW, Blamey RW. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast7, 335–339 (1998).
   Web of Science ®Google Scholar
• Fennessy M, Bates T, Macrae K, Riley D, Houghton J, Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br. J. Surg.91, 699–704 (2004).
   PubMed Web of Science ®Google Scholar
• Mustacchi G, Ceccherini R, Dilani S et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long term results of the Phase III randomized controlled multicenter GRETA trial. Ann. Oncol.14, 414–420 (2003).
   PubMed Web of Science ®Google Scholar
• Fentiman IS, Christiaens M-R, Paridaens R et al. Treatment of operable breast cancer in the elderly: a randomized clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur. J. Cancer39, 309–316 (2003).
   PubMed Web of Science ®Google Scholar
• Barnadas A, Gil M, Gonzalez S, Tusquets I, Munoz M, Arcusa A. Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a Phase II trial. Br. J. Cancer100(3), 442–449 (2009).
   PubMed Web of Science ®Google Scholar
• Joensuu H, Ejlertsen B, Lonning PE. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncol.44, 23–31 (2005).
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JFR, Quaresma AJ et al. Fulvestrant, formerly ICI 182780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol.20, 3396–3403 (2002).
   PubMed Web of Science ®Google Scholar
• Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol.20, 3386–3395 (2002).
   PubMed Web of Science ®Google Scholar
• Vergote I, Robertson JFR. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Br. J. Cancer90, S11–S14 (2004).
   Google Scholar
• Bottini A, Generali D, Brizzi MP et al. Randomized Phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J. Clin. Oncol.24, 3623–3628 (2006).
   PubMed Web of Science ®Google Scholar
• Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med.144, 753–761 (2006).
   PubMed Web of Science ®Google Scholar
• Botteman M, Barghout V, Stephens J et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann. Oncol.17, 1072–1082 (2006).
   PubMed Web of Science ®Google Scholar